MY120841A - Methods of inducing cancer cell death and tumor regression - Google Patents

Methods of inducing cancer cell death and tumor regression

Info

Publication number
MY120841A
MY120841A MYPI20001455A MYPI20001455A MY120841A MY 120841 A MY120841 A MY 120841A MY PI20001455 A MYPI20001455 A MY PI20001455A MY PI20001455 A MYPI20001455 A MY PI20001455A MY 120841 A MY120841 A MY 120841A
Authority
MY
Malaysia
Prior art keywords
methods
cell death
cancer cell
tumor regression
inducing cancer
Prior art date
Application number
MYPI20001455A
Other languages
English (en)
Inventor
Walter R Bishop
Diana L Brassard
Tattanahalli L Nagabhushan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MY120841A publication Critical patent/MY120841A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI20001455A 1999-04-09 2000-04-07 Methods of inducing cancer cell death and tumor regression MY120841A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/289,255 US6316462B1 (en) 1999-04-09 1999-04-09 Methods of inducing cancer cell death and tumor regression

Publications (1)

Publication Number Publication Date
MY120841A true MY120841A (en) 2005-11-30

Family

ID=23110723

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20001455A MY120841A (en) 1999-04-09 2000-04-07 Methods of inducing cancer cell death and tumor regression

Country Status (24)

Country Link
US (1) US6316462B1 (enExample)
EP (1) EP1165078B1 (enExample)
JP (1) JP2003529540A (enExample)
CN (1) CN100421661C (enExample)
AR (1) AR023400A1 (enExample)
AT (1) ATE347360T1 (enExample)
AU (1) AU783177B2 (enExample)
BR (1) BR0009670A (enExample)
CA (1) CA2364675A1 (enExample)
CY (1) CY1107545T1 (enExample)
DE (1) DE60032226T2 (enExample)
DK (1) DK1165078T3 (enExample)
ES (1) ES2275505T3 (enExample)
HK (1) HK1038512B (enExample)
HU (1) HUP0200773A3 (enExample)
MX (1) MXPA01010211A (enExample)
MY (1) MY120841A (enExample)
NO (1) NO329133B1 (enExample)
NZ (1) NZ514628A (enExample)
PE (1) PE20010025A1 (enExample)
PT (1) PT1165078E (enExample)
TW (1) TWI255184B (enExample)
WO (1) WO2000061145A1 (enExample)
ZA (1) ZA200108258B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
MXPA01013458A (es) * 1999-06-25 2002-07-30 Genentech Inc Anticuerpos humanizados anti-erbb2 y tratamiento con anticuerpos anti-erbb2.
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
WO2001064226A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
MXPA02011379A (es) 2000-05-19 2003-06-06 Genentech Inc Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
BR0114430A (pt) * 2000-10-05 2004-01-06 George Q Daley Processos para a indução da morte de células cancerìgenas e para a regressão de tumor
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EP1353924A1 (en) * 2001-01-18 2003-10-22 Schering Corporation Synthesis of temozolomide and analogs
NZ516873A (en) * 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
US6984389B2 (en) * 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
RU2376029C2 (ru) 2002-04-25 2009-12-20 Юниверсити Оф Коннектикут Хелт Сентер Применение белков теплового шока для улучшения терапевтического эффекта невакцинного лечебного воздействия
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
AU2003287366A1 (en) * 2002-10-31 2004-06-07 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US8168568B1 (en) 2003-03-10 2012-05-01 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Combinatorial therapy for protein signaling diseases
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
DE602004011340T2 (de) 2003-05-20 2008-11-06 Bayer Healthcare Llc Diaryl-harnstoffe mit kinasehemmender wirkung
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
EP1691812A4 (en) 2003-11-20 2010-01-13 Childrens Hosp Medical Center GTPASE INHIBITORS AND METHOD OF USE
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
EP1718767B1 (en) * 2004-02-03 2012-04-11 The Regents Of The University Of Michigan Compositions for treating breast and pancreatic cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
EP2283831A3 (en) * 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
KR20200058588A (ko) 2005-01-21 2020-05-27 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
DK2161336T4 (en) * 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
CN101287761A (zh) * 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
CN101500597A (zh) 2005-06-17 2009-08-05 伊姆克罗尼系统公司 治疗转移性骨癌的受体拮抗剂
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
EP1920048A4 (en) 2005-07-29 2009-12-09 Childrens Hosp Medical Center GTASE INHIBITORS AND USE METHOD AND CRYSTAL STRUCTURE OF RAC-1 GTASE
KR101353706B1 (ko) * 2006-02-03 2014-02-18 유니버시티 오브 워싱톤 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
JP5399900B2 (ja) * 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｇｆｂｐ２インヒビター
EP2076259A2 (en) * 2006-10-25 2009-07-08 Schering Corporation Methods of treating ovarian cancer
KR20150039212A (ko) 2007-03-02 2015-04-09 제넨테크, 인크. 낮은 ｈｅｒ３ 발현을 기초로 한 ｈｅｒ 이량체화 억제제에 대한 반응 예측
MX2009012054A (es) 2007-05-08 2009-11-19 Schering Corp Metodos de tratamiento que usan formulaciones intravenosas que comprenden temozolomida.
SI2171090T1 (sl) 2007-06-08 2013-07-31 Genentech, Inc. Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2175885B1 (en) * 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
US20110129549A1 (en) * 2008-04-17 2011-06-02 Liu Julie F Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
KR20110075029A (ko) * 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
WO2010136569A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2013025853A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
EP2831115A1 (en) 2012-03-27 2015-02-04 F. Hoffmann-La Roche AG Diagnosis and treatments relating to her3 inhibitors
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US11331312B2 (en) * 2014-04-25 2022-05-17 Memorial Sloan-Kettering Cancer Center Treatment of H-Ras-driven tumors
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
JP7718659B2 (ja) 2019-08-16 2025-08-05 チルドレンズ ホスピタル メディカル センター Ｃｄｃ４２特異的阻害剤で対象を治療する方法
EP4635574A2 (en) 2021-11-02 2025-10-22 Semmelweis Egyetem Combination therapy to treat kras mutant cancers
CN120053663B (zh) * 2024-04-15 2025-12-12 天津医科大学 Sp/klf转录因子抑制剂与去乙酰化酶抑制剂组合的制药用途

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214092A1 (en) * 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
WO1995010516A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5464840A (en) * 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
WO1996031477A1 (en) * 1995-04-07 1996-10-10 Schering Corporation Tricyclic compounds useful for inhibition of farnesyl protein transferase
WO1997038697A1 (en) * 1996-04-15 1997-10-23 The Trustees Of The University Of Pennsylvania Sensitization of cells to radiation and chemotherapy
WO1998000113A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5714609A (en) * 1993-10-15 1998-02-03 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
EP0856315A1 (en) * 1995-08-09 1998-08-05 Banyu Pharmaceutical Co., Ltd. Medicinal composition
US5858411A (en) * 1994-12-19 1999-01-12 Daiichi Pharmaceutical Co., Ltd. Sustained-release granular preparations and production process thereof
WO1999032118A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2546577B2 (de) 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA1341044C (en) 1988-04-28 2000-07-04 Frank J. Villani Benzopyrido piperidine, piperidylidene and peperazine compounds, compositions, methods of manufacture and methods of use
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
AU665341B2 (en) * 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JPH07505394A (ja) 1992-03-27 1995-06-15 シェリング・コーポレーション 橋渡しビスアリールカルビノール誘導体，組成物および使用法
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
FR2698560B1 (fr) 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU699043B2 (en) 1993-10-15 1998-11-19 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5523095A (en) 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
TW350844B (en) 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
EP0906099A4 (en) 1996-04-03 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
CA2251955A1 (en) 1996-04-18 1997-10-23 Nancy E. Kohl A method of treating cancer
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5861395A (en) 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
BR9712980A (pt) 1996-09-13 2000-04-18 Schering Corp Compostos úteis para inibição de transferase de proteina de farnesila
US5985879A (en) 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5965570A (en) 1996-09-13 1999-10-12 Schering Corporation Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
CA2282683A1 (en) 1997-02-18 1998-08-20 Canji, Inc. Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
US5939416A (en) 1997-06-17 1999-08-17 Schering Corporation Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
US5877177A (en) 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5925639A (en) 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US5852034A (en) 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US5958940A (en) 1997-09-11 1999-09-28 Schering Corporation Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0214092A1 (en) * 1985-08-08 1987-03-11 Ciba-Geigy Ag Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5714609A (en) * 1993-10-15 1998-02-03 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1995010516A1 (en) * 1993-10-15 1995-04-20 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5464840A (en) * 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5858411A (en) * 1994-12-19 1999-01-12 Daiichi Pharmaceutical Co., Ltd. Sustained-release granular preparations and production process thereof
WO1996031477A1 (en) * 1995-04-07 1996-10-10 Schering Corporation Tricyclic compounds useful for inhibition of farnesyl protein transferase
US5672611A (en) * 1995-04-07 1997-09-30 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
EP0856315A1 (en) * 1995-08-09 1998-08-05 Banyu Pharmaceutical Co., Ltd. Medicinal composition
WO1997038697A1 (en) * 1996-04-15 1997-10-23 The Trustees Of The University Of Pennsylvania Sensitization of cells to radiation and chemotherapy
WO1998000113A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5958890A (en) * 1996-09-13 1999-09-28 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
WO1999032118A1 (en) * 1997-12-22 1999-07-01 Schering Corporation Molecular dispersion composition with enhanced bioavailability

Also Published As

Publication number Publication date
DE60032226D1 (de) 2007-01-18
WO2000061145A1 (en) 2000-10-19
PE20010025A1 (es) 2001-02-05
NO329133B1 (no) 2010-08-30
EP1165078A1 (en) 2002-01-02
HK1038512A1 (en) 2002-03-22
DE60032226T2 (de) 2007-10-11
AR023400A1 (es) 2002-09-04
TWI255184B (en) 2006-05-21
ES2275505T3 (es) 2007-06-16
JP2003529540A (ja) 2003-10-07
EP1165078B1 (en) 2006-12-06
NO20014897D0 (no) 2001-10-08
NO20014897L (no) 2001-12-10
AU783177B2 (en) 2005-09-29
AU4204100A (en) 2000-11-14
NZ514628A (en) 2004-01-30
US6316462B1 (en) 2001-11-13
PT1165078E (pt) 2007-02-28
ZA200108258B (en) 2003-03-26
HUP0200773A2 (hu) 2002-07-29
DK1165078T3 (da) 2007-04-16
HUP0200773A3 (en) 2003-04-28
BR0009670A (pt) 2002-01-15
ATE347360T1 (de) 2006-12-15
CN1364084A (zh) 2002-08-14
CN100421661C (zh) 2008-10-01
CA2364675A1 (en) 2000-10-19
HK1038512B (en) 2007-04-27
MXPA01010211A (es) 2002-09-18
CY1107545T1 (el) 2013-03-13

Similar Documents

Publication Publication Date Title
MY120841A (en) Methods of inducing cancer cell death and tumor regression
HK1052870A1 (zh) 诱导癌细胞死亡和肿瘤消退的方法
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
EA200100111A1 (ru) Ингибиторы фарнезилпротеинтрансферазы, обладающие in vivo радиосенсибилизирующими свойствами
PL338555A1 (en) Method of preventing or treating oestrogen-dependent diseases and disorders
BR9810465A (pt) Inibidores da farnesiltransferase de proteìnas
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
ATE415161T1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
WO2001064252A3 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
MY137303A (en) Methods for treating proliferative diseases
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
DK1276482T3 (da) Kombinationskemoterapi
ATE285247T1 (de) Krebstherapie mit lymphotoxin
AP9801261A0 (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
WO1998007415A3 (en) Methods for prevention of cellular proliferation and restenosis
ECSP003417A (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
NZ509646A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas
DE69807166D1 (de) Prostata-spezifische Antigen Inhibitore
MX9703208A (es) Tetra-y pentapeptidos substituidos inhibidores de proteina; farnesil transferasa.
UA32153A (uk) Спосіб формування трансплантату для зведення на промежину при черевно-анальних резекціях прямої кишки
UA23977A (uk) Іhгібітор росту злоякісhих клітиh